MP11-07 RADIOLIGAND THERAPY WITH 177 Lu-PSMA-I&T IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONCOLOGICAL OUTCOMES AND TOXICITY PROFILE

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP11-07 RADIOLIGAND THERAPY WITH 177Lu-PSMA-I&T IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONCOLOGICAL OUTCOMES AND TOXICITY PROFILE Mehmet Onur Demirkol, Baris Esen, Melis Sen, Burcu Ucar, Sevgilay Kurtuldu, Nil Molinas Mandel, Sevil Bavbek, Okan Falay, Derya Tilki, and Tarik Esen Mehmet Onur DemirkolMehmet Onur Demirkol More articles by this author , Baris EsenBaris Esen More articles by this author , Melis SenMelis Sen More articles by this author , Burcu UcarBurcu Ucar More articles by this author , Sevgilay KurtulduSevgilay Kurtuldu More articles by this author , Nil Molinas MandelNil Molinas Mandel More articles by this author , Sevil BavbekSevil Bavbek More articles by this author , Okan FalayOkan Falay More articles by this author , Derya TilkiDerya Tilki More articles by this author , and Tarik EsenTarik Esen More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003226.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prostate-specific membrane antigen (PSMA) targeted radioligand therapy (RLT) with 177Lu-PSMA-617 is associated with prolonged overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). Data regarding the oncological efficacy and toxicity profile of 177Lu-PSMA-I&T is limited. Herein, we aimed to investigate the oncological outcomes and toxicity profile of 177Lu-PSMA-I&T RLT in patients with mCRPC. METHODS: A total of 33 consecutive patients with mCRPC were treated with a total of 88 cycles (median 2 cycles, range 1-7) of 177Lu-PSMA-I&T RLT. The 177Lu-PSMA-I&T was given with a median activity of 7.5 GBq (IQR: 6.7 – 8.1) per cycle. Response to RLT were assessed according to prostate-specific antigen (PSA) changes and imaging response. Oncological outcomes were reported using clinical progression-free survival (cPFS), and overall survival (OS). Time interval from the first RLT cycle to any radiological or biochemical progression was considered clinical progression-free survival (cPFS). Common Toxicity Criteria for Adverse Events (CTCAE) criteria were utilized to assess toxicity. RESULTS: The mean patient age at the time of the first RLT cycle was 71.6 ± 10.7 years. Any PSA decline was detected in 22 (69%) cases after RLT. The number of patients achieving PSA declines of ≥30% and ≥50% were 18 (56%) and 11 (34%), respectively (Figure 1). The cPFS and OS after first cycle of RLT was 6.3 and 21.4 months, respectively. During RLT, nephrotoxicity occurred in 4 cases (12.1%); CTCAE grade according to estimated glomerular filtration rate worsening from I to II (n=2), II to III (n=1), III to IV (n=1). Six patients (18.2%) experienced a grade I/II myelotoxicity and 3 cases (9.1%) had grade III/IV myelotoxicity. CONCLUSIONS: 177Lu-PSMA-I&T RLT achieved a good PSA response (≥30%) in more than half of the patients with mCRPC with an acceptable toxicity profile. Further studies are required to assess the role of 177Lu-PSMA-I&T RLT in mCRPC. Source of Funding: European Urological Scholarship Programme through a 1-year research scholarship (to B.E.) © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e125 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Mehmet Onur Demirkol More articles by this author Baris Esen More articles by this author Melis Sen More articles by this author Burcu Ucar More articles by this author Sevgilay Kurtuldu More articles by this author Nil Molinas Mandel More articles by this author Sevil Bavbek More articles by this author Okan Falay More articles by this author Derya Tilki More articles by this author Tarik Esen More articles by this author Expand All Advertisement PDF downloadLoading ...